METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORS
Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.
1 .- 11 . (canceled)
13 . A method of treating an estrogen receptor positive breast cancer in a subject, wherein the estrogen receptor positive breast cancer is resistant to an estrogen receptor modulator, the method comprising administering a composition comprising a salt of (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino}-4-methoxyphenyl}-5,6,7,8-tetrahydronaphthalen-2-ol.
14 . The method of claim 13 , wherein the estrogen receptor positive breast cancer is de novo resistant to the estrogen receptor modulator.
15 . The method of claim 13 , wherein the resistance to the estrogen receptor modulator is acquired.
16 . The method of claim 13 , wherein the estrogen receptor modulator is tamoxifen, idoxifene, raloxifene or ICI 182,780.
17 . The method of claim 13 , wherein an effective amount of the composition is administered.
18 . The method of claim 17 , wherein the effective amount comprises a high dosage.
19 . The method of claim 18 , wherein the high dosage is more than about 20 mg/kg.
20 . The method of claim 17 , wherein the effective amount is from about 200 mg/day to about 500 mg/day.
21 . The method of claim 20 , wherein the effective amount is about 400 mg/day.
22 . The method of claim 13 , wherein the composition is administered by oral administration, intravenous administration, intradermal injection, intramuscular injection or subcutaneous injection.
23 . The method of claim 13 , further comprising administering an effective amount of at least one compound selected from the group consisting of a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6 inhibitor), an antiestrogen, a ligand of retinoic acid or retinoxic X receptor, an antiprogestin, an antiandrogen, vitamin D or metabolite thereof, a farnesyl transferase inhibitor, a PPARα or gamma agonist and a MAP kinase inhibitor.